Novo Nordisk reports development milestone for obesity candidate LX9851
The asset, licensed from Lexicon, advances in Novo's obesity pipeline as the company works to rebuild its cardiometabolic portfolio.
TR
By Tom Reyes · Markets Editor
Aug 24 03:00 ETSource: Yahoo Finance
The wire
- 01Novo Nordisk said it reached a development milestone for LX9851, an obesity drug candidate in its pipeline.
- 02Pipeline progress matters for operators tracking what follows semaglutide as Novo faces competitive pressure in obesity.
- 03No trial data, timing or endpoint details accompany the milestone disclosure, so the clinical significance remains unclear.
From the source
Read at finance.yahoo.comNovo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
